Application of berberine in tolerant DC cell culture
By adding berberine and cytokines to the tolerant DC cell culture medium and combining autologous plasma, the induction efficiency and immune tolerance of tolerant DC cells are improved, and the induction of tolerant DC cells in the prior art is solved. The problem of low efficiency has achieved large-scale production and clinical application of tolerant DC cells.
Patent Information
- Application Number
- CN202411257877.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-26
AI Technical Summary
The induction efficiency of existing tolerant DC cells is inefficient and cannot meet clinical needs.
Add berberine to the medium of tolerant DC cells, and combine cytokines such as GM-CSF, IL-4 and TGF-β, as well as autologous plasma to prepare a culture medium containing 0.25-5 μM berberine for use in the culture medium. Induce and culture tolerant DC cells.
Improve the content and immune tolerance of tolerant DC cells, reduce the expression levels of co-stimulatory molecules CD80, CD83, CD86, and HLA-DR, promote the culture and large-scale production of tolerant DC cells, and is used for clinical applications. Provide strong support.
Smart Images

Figure CN119020284A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of DC cell culture, and in particular to an application of berberine in tolerant DC cell culture. Background Art
[0002] Immune tolerance refers to a state in which self- or harmless foreign antigens are rendered quiescent through various mechanisms. This process does not cause immune damage to the body and helps maintain autoimmune stability. Clinically, immune tolerance can be used to treat autoimmune diseases, prevent transplant rejection, and control allergic reactions.
[0003] DC cells, full name dendritic cells (DCs), are the most powerful professional antigen-presenting cells in the body. Tolerogenic Dendritic Cells (tolDCs) are a type of dendritic cells with the ability to induce immune tolerance. They have the characteristics of low expression of co-stimulatory molecules, such as CD80, CD86, etc. These molecules play an important role in activating T cells. Low expression of co-stimulatory molecules makes tDCs unable to effectively activate T cells, thereby inducing immune tolerance. The immune tolerance ability of tolerant DC cells makes them important in clinical applications. By modifying or differentiating tolerant DC cells in vitro and returning them to patients, it is expected to achieve immunomodulatory treatment of diseases, which has broad application prospects.
[0004] Currently, cytokine induction is used to induce tolerant DC cells, such as adding IL-10 and transforming growth factor-β (TGF-β), or combining vitamin DC, to make them tolerant. However, its induction efficiency is low and cannot meet the large clinical needs. Therefore, how to improve the induction and culture efficiency of tolerant DC cells to produce clinical-grade products is an urgent problem to be solved. Summary of the Invention
[0005] The present invention provides the use of berberine in culturing tolerant DC cells. The main purpose of the present invention is to solve the problem of induction efficiency of tolerant DC cells in existing culture technologies.
[0006] Content of the present invention is as follows:
[0007] The first aspect of the present invention seeks to protect the use of berberine in culturing tolerogenic DC cells.
[0008] Berberine, also known as berberine, is a quaternary ammonium alkaloid isolated from the traditional Chinese medicine Coptis chinensis (Coptis chinensis) and is the main active antibacterial ingredient in the herb. Berberine is currently used clinically to treat intestinal infections such as gastroenteritis and bacillary dysentery. It can also be used to treat conjunctivitis and suppurative otitis media.
[0009] The applicants of the present invention have discovered that berberine is beneficial to the culture of tolerant DC cells. Its specific application in the culture medium for tolerant DC cell culture can further enhance immune tolerance and increase the content of tolerant DC cells, which plays an important role in the research and potential clinical application of tolerant DC cells.
[0010] As a preferred embodiment of the first aspect of the present invention, the concentration of berberine in the tolerogenic DC cell culture is 0.25-5 μM.
[0011] As a second aspect of the present invention, the present invention claims protection for a tolerogenic DC cell culture medium, comprising: a basal culture medium, cytokines, berberine and autologous plasma, wherein the concentration of the berberine is 0.25 to 5 μM, and the cytokines include 100 to 1000 U / mL GM-CSF, 10 to 50 ng / mL IL-4, and 100 to 1000 U / mL TGF-β.
[0012] Adding berberine to the tolerant DC cell culture medium, within the concentration range defined by the present invention, can further induce immune tolerance, which is beneficial to the culture of tolerant DC cells.
[0013] The tolerant DC cell culture medium also includes cytokines, autologous plasma and basal culture medium, and the remaining components are used to provide necessary nutrition and a suitable environment for the culture of tolerant DC cells and to induce the cells to be cultured to differentiate into DC cells or tolerant DC cells.
[0014] A further embodiment of the tolerogenic DC cell culture medium is that the amount of autologous plasma added is 5-10%.
[0015] A further embodiment of the tolerogenic DC cell culture medium is that the cytokines include 500 U / mL GM-CSF, 50 ng / mL IL-4, and 700 U / mL TGF-β.
[0016] A further embodiment of the tolerogenic DC cell culture medium is that the basic culture medium includes one of AIM-V culture medium, KBM-581 culture medium, and RPMI-1640.
[0017] A further embodiment of the tolerogenic DC cell culture medium is that the berberine content is 5 μM.
[0018] As a third aspect of the present invention, the present invention also claims protection for a method for culturing tolerant DC cells. The tolerant DC cell culturing method is based on culturing tolerant DC cells using the tolerant DC cell culture medium. The method is simple, effective, and easy to operate, and can achieve large-scale induced culture of tolerant DC cells.
[0019] The method for culturing tolerant DC cells comprises:
[0020] Obtaining cells to be processed;
[0021] The cells to be treated are inoculated into a culture vessel and cultured for a first predetermined time using a basal culture medium. Non-adherent cells are discarded, and then the tolerogenic DC cell culture medium as defined in the above scheme is added and cultured for a second predetermined time. After the culture is completed, the target cells are collected for detection.
[0022] As the method for culturing the tolerant DC cells, a preferred embodiment is: the cells to be treated are PBMCs, the first predetermined culture time is 1-4 hours, the second predetermined culture time is 7 days, and during the second culture time, the tolerant DC cell culture medium is replenished with fluid.
[0023] As another aspect of the present invention, the present invention also claims protection for a kit, which comprises any one of the tolerogenic DC cell culture media, and is used for culturing, inducing and / or preparing exosomes from the supernatant of tolerogenic DC cells.
[0024] The kit containing the above-mentioned tolerant DC cell culture medium can be used for culturing tolerant DC cells, is easy and flexible to use, can be mass-produced, and is convenient for clinical application.
[0025] Beneficial effects:
[0026] The present invention provides the use of berberine in the culture of tolerant DC cells. The addition of berberine enhances immune tolerance and is beneficial for the culture of tolerant DC cells. Cells cultured in a tolerant DC cell culture medium containing berberine showed reduced expression levels of co-stimulatory molecules CD80, CD83, CD86, and HLA-DR, indicating that the addition of berberine is beneficial for the culture of tolerant DC cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Schematic diagram of the expression levels of the co-stimulatory molecule HLA-DR in different experimental examples and comparative examples.
[0028] Figure 2 Schematic diagram of the expression levels of co-stimulatory molecule CD80 in different experimental examples and comparative examples;
[0029] Figure 3 Schematic diagram of the expression levels of co-stimulatory molecule CD83 in different experimental examples and comparative examples;
[0030] Figure 4 Schematic diagram of the expression levels of the co-stimulatory molecule CD86 in different experimental examples and comparative examples. DETAILED DESCRIPTION
[0031] To make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0032] The inventors of the present invention have found that applying berberine to the culture of tolerant DC cells can increase their immune tolerance, which is beneficial to the culture of tolerant DC cells and provides strong support for subsequent clinical research and use of tolerant DC cells.
[0033] Specifically, berberine is applied to tolerant DC cells, specifically in the form of a corresponding culture medium and a conversion product based on the corresponding culture medium, such as a kit.
[0034] Specifically, the application of berberine in tolerant DC cell culture can be a tolerant DC cell culture medium, which includes: basal culture medium, cytokines, berberine and autologous plasma.
[0035] The concentrations added to each component are as follows: the concentration of berberine is 0.25-5 μM, specifically 0.25 μM, 1 μM, 2 μM, 4 μM, and 5 μM.
[0036] The cytokines include 100-1000 U / mL GM-CSF, 10-50 ng / mL IL-4, and 100-1000 U / mL TGF-β. GM-CSF (granulocyte-macrophage colony-stimulating factor) promotes the differentiation of monocytes into large macrophage-like cells, thereby enhancing the cells' antigen presentation function and increasing the activity and number of DCs. IL-4 (interleukin-4) inhibits the excessive growth of macrophages, thereby guiding monocytes to differentiate into DCs. GM-CSF and IL-4 synergistically induce PBMC-directed DC differentiation. TGF-β promotes the transformation of immature DCs into tolerogenic DCs, rather than mature DCs.
[0037] Specifically, the added concentration of GM-CSF can be 100 U / mL, 200 U / mL, 400 U / mL, 500 U / mL, 700 U / mL, and 1000 U / mL; the added concentration of IL-4 can be 10 ng / mL, 20 ng / mL, 40 ng / mL, and 50 ng / mL; the added concentration of TGF-β can be 100 U / mL, 200 U / mL, 400 U / mL, 500 U / mL, 700 U / mL, 900 U / mL, and 1000 U / mL.
[0038] The tolerogenic DC cell culture medium also includes autologous plasma in an amount of 5-10%, preferably 10%. The addition of autologous plasma provides necessary growth factors for the cultured cells, thereby supporting the growth and development of the cells.
[0039] The present invention also provides a method for culturing the above-mentioned tolerant DC cells, comprising:
[0040] Obtaining cells to be processed;
[0041] The cells to be treated are inoculated into a culture vessel and cultured with a basal culture medium for a first predetermined time. Non-adherent cells are discarded, and then the tolerant DC cell culture medium is added to continue culturing for a second predetermined time. After the culture is completed, the target cells are collected for detection.
[0042] Specifically, in the present invention, PBMCs are used as the cells to be processed because they are easily available, abundant in number, and easy to culture and manipulate in vitro. Other approaches may also use bone marrow-derived hematopoietic stem cells, but their collection is limited.
[0043] After obtaining PBMCs, the PBMCs may be washed with PBS buffer and then cultured for a first predetermined culture time for separation and purification.
[0044] Specifically, the separation and purification scheme of the present invention is as follows: PBMCs are inoculated into a culture vessel, separated by utilizing the adherence ability of monocytes, and non-adherent cells are removed by washing to preliminarily enrich monocytes for separation and purification. In this stage, the culture time can be 1-4 hours, preferably 2 hours.
[0045] The basal culture medium in the adherence stage can be selected from the basal culture medium defined in this protocol, such as AIM-V culture medium, KBM-581 culture medium, and RPMI-1640 culture dish.
[0046] Specifically, the culture vessel can be a 6-well plate, a T25 culture flask, a T75 culture flask, etc., and can be selected according to the culture density and culture conditions.
[0047] The isolated and purified monocytes are added to the culture medium of the present invention and cultured for a second predetermined time, specifically 7 days. During the culture process, fresh culture medium is supplemented according to the culture conditions to ensure cell growth needs. Specifically, the replenishment time is once every 2-3 days.
[0048] After the culture was completed, adherent cells were scraped with a cell scraper for detection.
[0049] Cytokines and berberine are used to induce monocytes to differentiate into dendritic cells and promote the formation of immune tolerance. The addition of autologous plasma can better ensure cell growth. The immune tolerance of cells cultured using this culture medium and culture method is improved.
[0050] In order to better illustrate the technical effects of the technical solution of the present invention, the present invention constructed the following experimental examples and comparative examples for testing.
[0051] Experimental Example 1
[0052] The tolerogenic DC cell culture medium of Experimental Example 1 includes:
[0053] AIM-V medium;
[0054] Complete culture medium included cytokines, 500 U / mL GM-CSF, 50 ng / mL IL-4, and 700 U / mL TGF-β;
[0055] Complete medium including 10% autologous plasma
[0056] Experimental Example 2
[0057] The tolerogenic DC cell culture medium of Experimental Example 2 includes:
[0058] AIM-V medium;
[0059] Complete culture medium included cytokines, 500 U / mL GM-CSF, 50 ng / mL IL-4, and 700 U / mL TGF-β;
[0060] Complete medium included 0.25 μM berberine;
[0061] Complete culture medium included 10% autologous plasma.
[0062] Experimental Example 3
[0063] The tolerogenic DC cell culture medium of Experimental Example 3 includes:
[0064] AIM-V medium;
[0065] Complete culture medium included cytokines, 500 U / mL GM-CSF, 50 ng / mL IL-4, and 700 U / mL TGF-β;
[0066] Complete medium included 5 μM berberine;
[0067] Complete culture medium included 10% autologous plasma.
[0068] Comparative Example 1
[0069] The conventional DC cell culture medium of Comparative Example 1 was AIM-V culture medium;
[0070] Complete culture medium included cytokines, 500 U / mL GM-CSF, 50 ng / mL IL-4, and 700 U / mL TNF-α;
[0071] Complete culture medium included 10% autologous plasma.
[0072] The culture methods of Experimental Examples 1-3 and Comparative Examples are as follows:
[0073] S1: Human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient centrifugation;
[0074] S2: PBMCs were seeded into culture vessels at a density of 3 to 8 × 10 6 / mL, and added AIM-V basal medium for adherent culture for 2 hours, then discarded the non-adherent cells, added the above complete medium and continued to culture the adherent cells for 7 days, and added fresh complete medium every 2 to 3 days.
[0075] S3: After the culture is completed, adherent cells are scraped with a cell scraper and flow cytometry is used to analyze the immune phenotype of tolerant DCs, specifically the expression of costimulatory molecules HLA-DR, CD80, CD83, and CD86. The test results are as follows: Figure 1-4 shown.
[0076] Figure 1 The figure shows the expression level of HLA-DR, a co-stimulatory molecule in DC cells, in different experimental examples and comparative examples. HLA-DR is a molecule in the human leukocyte antigen (HLA) system. The HLA-DR positivity rate reflects the ability of these cells to present antigens to T cells. Low HLA-DR expression may lead to the inability of T cells to effectively recognize tumor cells, thereby promoting the formation of tumor immune tolerance. Figure 1 It was shown that the expression levels of the costimulatory molecule HLA-DR in Experimental Examples 2 and 3 were significantly lower than those in Comparative Example 1 and Experimental Example 1.
[0077] Figure 2 Schematic diagram of the expression level of DC cell co-stimulatory molecule CD80 in different experimental cases, such as Figure 2 The expression levels of the costimulatory molecule CD80 in Experimental Examples 2 and 3 were significantly lower than those in Comparative Example 1 and Experimental Example 1.
[0078] Figure 3 Schematic diagram of the expression level of DC costimulatory molecule CD83 in different experimental cases. CD83 is an important marker of dendritic cell (DC) maturation. Its positive rate reflects the maturation state and antigen presenting ability of DCs. Low CD83 positive rate may mean that DCs are not mature enough and have limited antigen presenting ability, leading to insufficient T cell activation and promoting immune tolerance. Figure 3 It was shown that the expression levels of the costimulatory molecule CD83 in Experimental Examples 2 and 3 were significantly lower than those in Comparative Example 1 and Experimental Example 1.
[0079] Figure 4 Schematic diagram of the expression level of DC cell co-stimulatory molecule CD86 in different experimental cases, such as Figure 4 It was shown that the expression levels of the costimulatory molecule CD86 in Experimental Examples 2 and 3 were significantly lower than those in Comparative Example 1 and Experimental Example 1.
[0080] In summary, the above test results show that berberine is beneficial to the culture of tolerant DC cells, and the above culture medium can increase the content of tolerant DC cells, which is beneficial to the large-scale production of tolerant DC cells and provides support for subsequent clinical applications.
[0081] As described above, the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the technical solutions described in the above embodiments can still be modified, or some of the technical features thereof can be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. Application of berberine in tolerant DC cell culture.
2. The use of berberine in tolerant DC cell culture according to claim 1, wherein the concentration of berberine in tolerant DC cell culture is 0.25 to 5 μM.
3. A tolerogenic DC cell culture medium, characterized in that: include: The invention relates to a basic culture medium, cytokines, berberine and autologous plasma, wherein the concentration of berberine is 0.25-5 μM, and the cytokines include 100-1000 U / mL GM-CSF, 10-50 ng / mL IL-4 and 100-1000 U / mL TGF-β.
4. The DC cell culture medium according to claim 3, characterized in that The amount of autologous plasma added is 5-10%.
5. The tolerogenic DC cell culture medium according to claim 3, characterized in that: The cytokines include 500U / mL GM-CSF, 50ng / mL IL-4, and 700U / mL TGF-β.
6. The tolerogenic DC cell culture medium according to claim 3, characterized in that The basic culture medium includes one of AIM-V culture medium, KBM-581 culture medium and RPMI-1640.
7. The tolerogenic DC cell culture medium according to claim 3, characterized in that The berberine was 5 μM.
8. A method for culturing tolerant DC cells, characterized in that: include: Obtaining cells to be processed; The cells to be treated are inoculated in a culture vessel, and cultured for a first predetermined time using a basic culture medium, and non-adherent cells are discarded. Then, the tolerant DC cell culture medium as described in any one of claims 3 to 7 is added and cultured for a second predetermined time. After the culture is completed, the target cells are collected for detection.
9. The method for culturing tolerant DC cells according to claim 8, characterized in that: The cells to be treated are PBMCs, the first predetermined culture time is 2-4 hours, the second predetermined culture time is 7 days, and during the second culture time, the tolerance DC cell culture medium is also replenished.
10. A kit, characterized in that: The kit comprises the tolerogenic DC cell culture medium according to any one of claims 3 to 7, and the kit is used for the culture, induction and / or supernatant exosome preparation of tolerogenic DC cells.
Citation Information
Cited By
Use of berberine in tolerogenic DC cells culturing
WO2026051739A1
